Aug 01, 2016
For over 100 years, immunotherapy has played a significant role in the treatment of cancer. Immune stimulatory agents such as Toll-like receptor (TLR) agonists, adoptive T cell and natural killer (NK) cell therapies, cytokine-based therapies etc. have gained approval for treatment of various indications. In 1980s, r...
Read More...
Apr 13, 2015
PD-1and PDL-1 are the next targeted agents in Oncology. These therapies have the enormous potential to treat cancer and have an excellent response in the increasing number of patients. Many experts say that out of all of the therapies, PD-1/PD-L1 inhibitors look to be the most promising in treating cancer. DelveIns...
Read More...
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Newsletter/Whitepaper